This topic contains a solution. Click here to go to the answer

Author Question: What is the primary limitation of using only two levels of a factor in a two-factor between-subjects ... (Read 36 times)

jho37

  • Hero Member
  • *****
  • Posts: 531
What is the primary limitation of using only two levels of a factor in a two-factor between-subjects design?
 
  a. It is simple to interpret.
 b. It increases the chances of demonstrating a significant mean difference.
 c. It tends to reduce the differences between the groups.
 d. It may not provide a complete picture of how the factor affects the dependent variable.

Question 2

Experimental design is generally strong against selection-history threats.
 
  a. True
  b. False
  Indicate whether the statement is true or false



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Pamela.irrgang@yahoo.com

  • Sr. Member
  • ****
  • Posts: 323
Answer to Question 1

d

Answer to Question 2

True




jho37

  • Member
  • Posts: 531
Reply 2 on: Jun 19, 2018
Gracias!


phuda

  • Member
  • Posts: 348
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

The term pharmacology is derived from the Greek words pharmakon("claim, medicine, poison, or remedy") and logos ("study").

Did you know?

In 1886, William Bates reported on the discovery of a substance produced by the adrenal gland that turned out to be epinephrine (adrenaline). In 1904, this drug was first artificially synthesized by Friedrich Stolz.

Did you know?

Essential fatty acids have been shown to be effective against ulcers, asthma, dental cavities, and skin disorders such as acne.

Did you know?

The average person is easily confused by the terms pharmaceutics and pharmacology, thinking they are one and the same. Whereas pharmaceutics is the science of preparing and dispensing drugs (otherwise known as the science of pharmacy), pharmacology is the study of medications.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library